Urinary markers of bladder carcinoma

Clinica Chimica Acta

Volumn 340, Issue 1-2, 2004, Pages 57-65

  Dey, Pranab ^a,b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b KUWAIT CANCER CONTROL CENTER   (Kuwait)

Author keywords

Biomarkers; Bladder cancer; Urinary markers; Urine

Indexed keywords

COMPLEMENT FACTOR H; CYTOKERATIN 18; CYTOKERATIN 19 FRAGMENT; CYTOKERATIN 20; FIBRIN DEGRADATION PRODUCT; HYALURONIC ACID; HYALURONIDASE; MINICHROMOSOME MAINTENANCE PROTEIN; MUCIN 7; NUCLEAR MATRIX PROTEIN; PROTEIN BLCA4; TELOMERASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

BLADDER CARCINOMA; BLADDER NECK; CANCER CYTODIAGNOSIS; CANCER DIAGNOSIS; CANCER SCREENING; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FLUOROMETRY; GENE EXPRESSION; HEMATURIA; HUMAN; IMMUNOASSAY; IMMUNOFLUORESCENCE TEST; LABORATORY TEST; MEDICAL EDUCATION; MITOSIS; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; URINALYSIS; URINE CYTOLOGY;

EID: 0842303112     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.11.008     Document Type: Review

References (63)

1. Stein J.P., Grossfeld G.D., Ginsberg D.A., Esrig D., Freeman J.A., Figueroa A.J.et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J. Urol. 160:1998;645-659.
2. Ianari A., Sernberg C.N., Rossetti A., VanBijn A., Deidda A., Giannarelli D.et al. Results of Bard BTA in monitoring patients with a history of transitional cell cancer of the badder. Urology. 49:1997;786-789.
3. Landman J., Chang Y., Kavaler E., Droller M.J., Liu B.C. Sensitivity and specificity of NMP-22, telomerase and BTA in the detection of human bladder cancer. Urology. 52:1998;398-402.
4. Johnston B., Morales A., Emerson L., Lundie M. Rapid detection of bladder cancer: a comparative study of point of care tests. J. Urol. 158:1997;2098-2101.
5. Wiener H.G., Mian C., Haitel A., Pycha A., Schatzl G., Marberger M. Can urine bound diagnostic tests replace cystoscopy in the management of bladder cancer? J. Urol. 159:1998;1876-1880.
6. Sarosdy M.F., Hudson M.A., Ellis W.J., Soloway M.S., deVereWhite R., Sheinfeld J.et al. Improved detection of recurrent bladder cancer using the Bard BTA stat test. Urology. 50:1997;349-353.
7. Pode D., Shapiro A., Wald M., Nativ O., Laufer M., Kaver I. Non invasive detection of bladder tumor with the BTA stat test. J. Urol. 161:1999;443-446.
8. Thomas L., Leyh H., Marberger M., Bombardieri E., Bassi P., Pagano F.et al. Multicenter trial of the quantitative BTA TRAK assay in the detection of bladder cancer. Clin. Chem. 45:1999;472-477.
9. Mahnert B., Tauber S., Kriegmair M., Schmitt U.M., Hasholzner U., Reiter W.et al. BTA-TRAK™ - a useful diagnostic tool in urinary bladder cancer? Anticancer Res. 19:1999;2615-2619.
10. Heicappell R., Wettig I.C., Schostak M., Muller M., Steiner U., Sauter T.et al. Quantitative detection of human complement factor H-related protein in transitional cell carcinoma of urinary bladder. Eur. Urol. 35:1999;81-87.
11. Ellis W.J., Blumenstein B.A., Ishak L.M., Enfield D.L.L. Clinical evaluation of the BTA TRAK assay and comparison to voided urine cytology and the Bard BTA test in patiens with recurrent bladder tumors. Multi. center study group. Urology. 50:1997;882-887.
12. Berezney R., Coffey D.S. Identification of a nuclear protein matrix. Biochem. Biophys. Res. Commun. 60:1974;1410-1417.
13. Pardoll D.M., Vogelstein B., Coffey D.S. A fixed site of DNA replication in cells. Cell. 19:1980;527-536.
14. Gordon J.N., Shu W.P., Schlussel R.N., Droller M.J., Liu B.C. Altered extracellular matrices influence cellular processes and nuclear matrix organizations of overlying human bladder urothelial cells. Cancer Res. 53:1993;4971-4977.
15. Yang C.H., Lambie E.J., Synder M. NuMA: an unusually long coiled-coil related protein in the mammalian nucleus. J. Cell Biol. 116:1992;1303-1317.
16. Keesee S.K., Briggman J.V., Thill G., Wu Y.J. Utilization of nuclear matrix proteins for cancer diagnosis. CRC Crit. Rev. Eukaryot. Gene Expr. 6:1996;189-214.
17. Landman J., Chang Y., Kavaler E., Droller M.J., Liu B.C.-S. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology. 52:1998;398-402.
18. Poulakis V., Witzsch U., Vries D., Altmannsberger H.-M., Manyak M.J., Becht E. A comparison of urinary nuclear matrix protein-22 and bladder tumor antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results. BJU Int. 88:2001;692-701.
19. Eissa S., Swellam M., Sadek M., Mourad S., Ahmady O., Khalifa A. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urinary cytology in the detection of bladder tumors. J. Urol. 168:2002;465-469.
20. Friedrich M.G., Hellstern A., Hautmann S.H., Graefen M., Conrad S., Huland E.et al. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA Stat and NMP22 tests. J. Urol. 168:2002;470-474.
21. Ponsky L.E., Sharma S., Pandrangi L., Kedia S., Nelson D., Agarwal A.et al. Screening and monitoring for bladder cancer: refining the use of NMP22. J. Urol. 166:2001;75-78.
22. Ramakumar S., Bhuiyan J., Besse J.A., Roberts S.G., Wollan P.C., Blute M.L.et al. Comparison of screening methods in the detection of bladder cancer. J. Urol. 161:1999;388-394.
23. Tsihlias J., Grossman H.B. The utility of fibrinl/fibrinogen degradation products in superficial bladder cancer. Urol. Clin. North Am. 27:2000;39-46.
24. Schmetter B.S., Habicht K.K., Lamm D.I., Morales A., Bander N.H., Grossman H.B.et al. A multicenter trial evaluation of the fibrin/fibrinogen degradation product test for detection and monitoring bladder cancer. J. Urol. 158:1997;801-805.
25. Pham H.T., Block N.L., Lokeshwar V.B. Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder cancer. Cancer Res. 57:1997;778-783.
26. Kundson W., Biswas C., Li X.-Q., Nemec R.E., O'Toole B.P. The role and regulation of tumor associated hyaluronan. Whelan J. The Biology of Hyaluronan. Ciba Foundation Symposium. 1989;150-169 Wiley, Chichister, NY.
27. Auvinen P.K., Parkkin E.N.J., Johansson R.T., Agren V.M., Tammi R.H., Eskelinen M.J.et al. Expression of Hyaluronan in benign and malignant lesions. Int. J. Cancer (Ped Oncol). 74:1997;477-481.
28. Kundson W. Tumor-associated hyaluronan. Am. J. Pathol. 6:1996;1721.
29. Peach R.J., Hollenbaugh D., Stamenkovic I., Aruffo A. Identification of hyaluronic acid binding in extracellular domain of CD44. J. Cell Biol. 122:1993;257-264.
30. Hobarth K., Maier U., Merberger M. Topical chemoprphylaxis of superficialbladder cancer by mitomycin C and adjuvant hyaluronidase. Eur. Urol. 21:1992;206-210.
31. Pham H.T., Block N.L., Lokehswar V.B. Tumor-derived hyaluronidase: a diagnostic urine marker for high grade bladder cancer. Cancer Res. 57:1997;778-783.
32. Lokeshwar V.B., Obek C., Pham H.T., Wei D., Young M.J., Duncan R.C.et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation grade. J. Urol. 163:2000;348-356.
33. Holt S.E., Shay J.W., Wright W.E. Refining the telomere-telomerase hypothesis of aging and cancer. Nat. Biotechnol. 14:1996;836-839.
34. Kavaler E., Landman J., Chang Y., Droller M.J., Liu B.C. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity. Cancer. 82:1998;708-714.
35. Yokota K., Kanda K., Inoue Y., Kanayama H., Kagawa S. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma. Br. J. Urol. 82:1998;727-732.
36. Myfield M.P., Shah T., Flannigan G.M., Hamilton Stewart P.A., Bibby M.C. Telomerase activity in malignant and benign bladder conditions. Int. J. Mol. Med. 1:1998;835-840.
37. Liu B.C.-S., Loughlin K.R. Telomerase in human bladder cancer. Urol. Clin. North Am. 27:2000;115-123.
38. Greider C.W. Telomerase length regulation. Annu. Rev. Biochem. 65:1996;337-365.
39. Ito H.K., Kyo S., Kanaya T., Takakura M., Inoue M., Namiki M. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer. Clin. Cancer Res. 4:1998;1603-1608.
40. Van der Poel H.G., Witjes J.A., van Stratum P., Boon M.E., Debruyne F.M., Schalken J.A. Quanticyt Karyometric analysis of bladder washing for patients with superficial bladder cancer. Urology. 48:1996;357-364.
41. Fradet Y., Lockhart C. Performance characteristics of a new monoclonal antibody test for bladder cancer: immunocyt™ Can. J. Urol. 4:1997;400-405.
42. Fradet Y., La Rue H., Parent-Vaugeois C., Bergeron A., Dufour C., Boucher L.et al. Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical codylomas. Int. J. Cancer. 46:1990;990-997.
43. Mian C., Pycha A., Wiener H., Haitel A., Lodde M., Marberger M. Immunocyt*: A New Tool for Detecting Transitional Cell Cancer of the Urinary Tract. 161:1999;1486-1489.
44. Pfister C., Chautard D., Devonec M., Perrin P., Chopin D., Rischmann P. et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study. J. Urol. 169(3):2003 (Mar.);921-924.
45. Kumar U.N., Dey P., Mondal A.K., Singh S.K., Vohra H. DNA flowcytometry and bladder irrigation cytology in detection of bladder carcinoma. Diagn. Cytopathol. 24:2001;153-156.
46. Planz B., Synek C., Robben J., Bocking A., Marberger M. Diagnostic accuracy of DNA image cytometry and urinary cytology with cell from voided urine in the detection of bladder cancer. Urology. 56:2000;782-786.
47. Badalament R.A., Hermansen D.K., Kimmel M., Gay H. The sensitivity of bladder wash flow cytometry, bladder wash cytology and voided cytology in the detection of bladder carcinoma. Cancer. 60:1987;1423-1427.
48. Gregoire M., Fradet Y., Mayer F., Tetu B., Bois R., Bedard G.et al. Diagnostic accuracy of urinary cytology and deoxyribonucleic acid flow cytometry and cytology on bladder washings during follow up for bladder tumor. J. Urol. 157:1997;1660-1664.
49. Hijazi A., Devonec M., Bouvier R., Revillard J.P. Flow cytometry study of cytokeratin 18 expression according to tumor grade and deoxyribonculei acid content in human bladder tumors. J. Urol. 141(3):1989 (March);522-526.
50. Moll R., Lowe A., Laufer J., Franke W.W. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 140:1992;427.
51. Buchumensky V., Klein A., Zemer R., Kessler O.J., Zinilichan S., Nissenkorn I. Cytokeratin-20: a new marker for early detection of bladder cell carcinoma. J. Urol. 160:1998;1971-1974.
52. Klein A., Zamer R., Buchumonsky V., Klaper R., Nissenkorn I. Expression of cytokeratin 20 in urinary cytology of patients with bladder carcinoma. Cancer. 82:1998;349-354.
53. Sanchez-Carbayo M., Urrutia M., Gonzalez de Buitrago J.M., Navajo J.A. Evaluation of two new urinary tumor markers: bladder tumor fibronectin and cytokeratin 18 for the diagnosis of bladder cancer. Clin. Cancer Res. 6(9):2000;3585-3594.
54. Nisman B., Barak V., Shapiro A., Golijanin D., Peretz T., Pode D. Evaluation of urine Cyfra 21-1 for the detection of primary and recurrent bladder carcinoma. Cancer. 94:2002;2914-2922.
55. Sandberg A.A., Berger C.S. Review of chromosome studies in urological tumors 11. Cytogenetics and molecular genetics of bladder cancer. J. Urol. 151:1994;545-560.
56. Halling K.C., King W., Sokolova I.A., Meyer R.G., Burkhardt H.M., Halling A.C.I. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J. Urol. 164:2000;1768-1775.
57. Konety B.R., Nguyen T.S., Dhir R. Detection of bladder cancer using a novel nuclear matrix protein BLCA-4. Clin. Cancer Res. 6:2000;2618-2625.
58. Retz M., Lehmann J., Amann E., Wullich B., Roder C., Stockle M. Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumor. J. Urol. 169(1):2003 (Jan.);86-89.
59. Sharp J.D., Hausladen D.A., Maher M.G., Wheeler M.A., Altieri D.C., Weiss R.M. Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front. Biosci. 7:2002 (Feb. 1);e36-e41.
60. Stoeber K., Swinn R., Prevost A.T., de Clive-Lowe P., Halsall I., Dilworth S.M.et al. Diagnosis of genitourinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments. J. Natl. Cancer Inst. 94(14):2002;1071-1079.
61. Glas A.S., Roos D., Deutekom M., Zwinderman A.H., Bossuyt P.M., Kurth K.H. Tumor markers in the diagnosis of primary bladder cancer A systematic review. J. Urol. 169(6):2003 (Jun.);1975-1982.
62. Lotan Y., Roehrborn C.G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology results of a comprehensive literature review and meta-analyses. Urology. 61(1):2003 (Jan);109-118.
63. Parekattil S.J., Fisher H.A., Kogan B.A. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer. J. Urol. 169(3): 2003 (Mar.);917-920.